---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-211645"
form_type: "8-K"
ticker: "ALDX"
cik: "0001341235"
company_name: "Aldeyra Therapeutics, Inc."
filed_at: "2024-09-03T23:59:59+00:00"
generated_at: "2026-05-31T06:35:21.429904+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aldeyra appoints Michael Alfieri as principal financial officer, Bruce Greenberg steps down

## Summary
- Michael Alfieri appointed as principal financial officer and principal accounting officer, effective Aug 31, 2024, via consulting agreement with Danforth Global, Inc.
- Bruce Greenberg stepped down from positions including SVP Finance, Interim CFO, and principal accounting officer as of Aug 31, 2024.
- Greenberg receives separation: six months base salary, lump-sum $125,895, and COBRA premium payments for up to six months.
- Greenberg will provide consulting services through Nov 30, 2024, with continued vesting of outstanding stock options.

## SEC filing metadata
- accession: 0001193125-24-211645
- form_type: 8-K
- ticker: ALDX
- cik: 0001341235
- company_name: Aldeyra Therapeutics, Inc.
- filed_at: 2024-09-03T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1341235/000119312524211645/0001193125-24-211645-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1341235/000119312524211645/d862679d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-211645
- JSON: https://secwatch.observer/filing/0001193125-24-211645.json
- Plain text: https://secwatch.observer/filing/0001193125-24-211645.txt

## Key facts
- Executive change
  Michael Alfieri was appointed as principal financial officer and principal accounting officer at Aldeyra Therapeutics, Inc..
  - Action: appointed
  - Role: principal financial officer and principal accounting officer
  source text: On August 29, 2024, the board of directors of Aldeyra Therapeutics, Inc. (the “Company”) approved the appointment of Michael Alfieri as the Company’s principal financial officer and principal accounting officer effective as of August 31, 2024 (the “Effective Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1341235/000119312524211645/0001193125-24-211645-index.htm
- Executive change
  Bruce Greenberg departed as Senior Vice President of Finance, Interim Chief Financial Officer at Aldeyra Therapeutics, Inc..
  - Action: stepped down
  - Role: Senior Vice President of Finance, Interim Chief Financial Officer
  source text: As previously disclosed by the Company, Bruce Greenberg stepped down from his positions with the Company, including as the Company’s Senior Vice President of Finance, Interim Chief Financial Officer and principal financial officer and principal accounting officer as of the Effective Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1341235/000119312524211645/0001193125-24-211645-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.